DOCSLIB.ORG

Fourth Quarter Product Sales of $2.13 Billion, up 11% Year Over Year

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fourth Quarter Product Sales of $2.13 Billion, up 11% Year Over Year Gilead Sciences Announces Fourth Quarter and Full Year 2011 Financial Results February 2, 2012 4:06 PM ET - Fourth Quarter Product Sales of $2.13 Billion, up 11% Year over Year - - Full Year 2011 Product Sales of $8.10 Billion, up 10% over 2010 - - Full Year 2011 Non-GAAP EPS of $3.86, up 5% over 2010 - - Full Year 2011 Operating Cash Flows of $3.64 Billion - FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 2, 2012-- Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the fourth quarter and full year 2011. Total revenues for the fourth quarter of 2011 increased 10 percent to $2.20 billion, from $2.00 billion for the fourth quarter of 2010. Net income for the fourth quarter of 2011 was $665.1 million, or $0.87 per diluted share, compared to $629.4 million, or $0.76 per diluted share for the fourth quarter of 2010. Non-GAAP net income for the fourth quarter of 2011, which excludes after-tax acquisition-related, restructuring and stock-based compensation expenses, was $743.1 million, or $0.97 per diluted share, compared to $779.3 million, or $0.95 per diluted share for the fourth quarter of 2010. Full year 2011 total revenues were $8.39 billion, up 5 percent compared to $7.95 billion for 2010. Net income for 2011 was $2.80 billion, or $3.55 per diluted share, compared to $2.90 billion, or $3.32 per diluted share for 2010. Non-GAAP net income for 2011, which excludes after-tax acquisition-related, restructuring and stock-based compensation expenses, was $3.04 billion, or $3.86 per diluted share, compared to $3.21 billion, or $3.69 per diluted share for 2010. Product Sales Product sales increased 11 percent to $2.13 billion for the fourth quarter of 2011, compared to $1.93 billion in the fourth quarter of 2010. For 2011, product sales increased 10 percent to $8.10 billion compared to $7.39 billion in 2010. This increase in product sales was driven primarily by Gilead’s antiviral franchise, resulting from continued growth in sales of Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Antiviral Franchise Antiviral product sales increased 9 percent to $1.86 billion in the fourth quarter of 2011, up from $1.70 billion for the same quarter of 2010, reflecting sales growth of 12 percent in the U.S. and 5 percent in Europe. For 2011, antiviral product sales increased 8 percent to $7.05 billion from $6.54 billion in 2010, reflecting sales growth of 9 percent in Europe and 6 percent in the U.S. ● Atripla Sales of Atripla increased 11 percent to $863.3 million for the fourth quarter of 2011, up from $775.2 million in the fourth quarter of 2010, reflecting sales growth of 11 percent in the U.S. and 10 percent in Europe. For 2011, Atripla sales increased 10 percent to $3.22 billion from $2.93 billion in 2010. ● Truvada Sales of Truvada increased 9 percent to $746.0 million for the fourth quarter of 2011, up from $681.7 million in the fourth quarter of 2010, reflecting sales growth of 10 percent in the U.S. and 5 percent in Europe. For 2011, Truvada sales increased 8 percent to $2.88 billion from $2.65 billion in 2010. ● Viread Sales of Viread® (tenofovir disoproxil fumarate) were consistent at $190.9 million for the fourth quarter of 2011, compared to Page 1/10 $191.1 million in the fourth quarter of 2010. For 2011, Viread sales increased 1 percent to $737.9 million from $732.2 million in 2010. ● Complera Sales of Complera® (emtricitabine 200 mg/ rilpilvirine 25 mg/ tenofovir disoproxil fumarate 300 mg) were $19.7 million for the fourth quarter of 2011 and $38.7 million for 2011. The U.S. Food and Drug Administration (FDA) approved Complera, a new once-daily, single-tablet complete HIV treatment regimen for patients new to therapy in August 2011. In November 2011, the European Commission granted marketing authorization for the product to be marketed in Europe with the trade name Eviplera®. Letairis Sales of Letairis® (ambrisentan) increased 23 percent to $78.7 million for the fourth quarter of 2011, up from $64.0 million for the fourth quarter of 2010. For 2011, Letairis sales increased 22 percent to $293.4 million from $240.3 million in 2010. Ranexa Sales of Ranexa® (ranolazine) increased 23 percent to $83.7 million for the fourth quarter of 2011, up from $67.8 million for the fourth quarter of 2010. For 2011, Ranexa sales increased 33 percent to $320.0 million from $239.8 million in 2010. Other Products Sales of other products were $151.1 million for the fourth quarter of 2011 compared to $150.4 million for the fourth quarter of 2010 and included AmBisome® (amphotericin B) liposome for injection, Hepsera® (adefovir dipivoxil), Emtriva® (emtricitabine) and Cayston® (aztreonam for inhalation solution). For 2011, sales of other products increased 2 percent to $612.7 million from $601.1 million in 2010. Royalty, Contract and Other Revenues Royalty, contract and other revenues from collaborations were $67.0 million in the fourth quarter of 2011, down 2 percent from $68.4 million in the fourth quarter of 2010. For 2011, royalty, contract and other revenues were $283.0 million, down 49 percent from $559.5 million in 2010, primarily due to lower Tamiflu royalties from F. Hoffmann-La Roche Ltd as pandemic planning initiatives worldwide have declined. Research and Development Research and development (R&D) expenses in the fourth quarter of 2011 were $402.2 million, compared to $392.8 million for the fourth quarter of 2010. Non-GAAP R&D expenses for the fourth quarter of 2011, which exclude acquisition-related, restructuring and stock-based compensation expenses, were $349.3 million, compared to $231.8 million for the fourth quarter of 2010. For 2011, R&D expenses were $1.23 billion compared to $1.07 billion in 2010. Non-GAAP R&D expenses for 2011 were $1.12 billion compared to $838.8 million in 2010. The increase in non-GAAP R&D expenses was due primarily to increased clinical activities and expenses associated with acquisitions, collaborations and continued advancements of our clinical pipeline. Selling, General and Administrative Selling, general and administrative (SG&A) expenses in the fourth quarter of 2011 were $346.2 million, compared to $280.2 million for the fourth quarter of 2010. Non-GAAP SG&A expenses for the fourth quarter of 2011, which exclude acquisition- related, restructuring and stock-based compensation expenses, were $289.9 million, compared to $239.3 million for the fourth quarter of 2010. For 2011, SG&A expenses were $1.24 billion compared to $1.04 billion in 2010. Non-GAAP SG&A expenses for 2011 were $1.09 billion compared to $912.6 million in 2010. The increase in non-GAAP SG&A expenses was driven primarily by the impact of the pharmaceutical excise tax resulting from the U.S. healthcare reform, increased expenses associated with the ongoing growth of Gilead’s business, and increased bad debt expense due to slower collections in certain Southern European countries. Page 2/10 Income Taxes The effective tax rate for 2011 was 23.6 percent compared to 26.2 percent for 2010. The decrease was primarily due to lower state taxes and the geographic mix of product sales, partially offset by the impact of the U.S. pharmaceutical excise tax. Net Foreign Currency Exchange Impact The net foreign currency exchange impact on fourth quarter 2011 revenues and pre-tax earnings was an unfavorable $21.2 million and $22.1 million, respectively, compared to the fourth quarter of 2010. The net foreign currency exchange impact on full year 2011 revenues and pre-tax earnings was a favorable $21.4 million and an unfavorable $18.6 million, respectively, compared to 2010. Cash, Cash Equivalents and Marketable Securities As of December 31, 2011, Gilead had cash, cash equivalents and marketable securities of $9.96 billion compared to $5.32 billion as of December 31, 2010, which included the proceeds from $3.70 billion of investment grade bonds raised to partially fund the Pharmasset, Inc. (Pharmasset) acquisition. Gilead generated $3.64 billion of operating cash flow in 2011 of which $978.1 million was generated in the fourth quarter of 2011. Acquisition of Pharmasset, Inc. In November, Gilead and Pharmasset announced that the companies had signed a definitive agreement under which Gilead would acquire Pharmasset for $137 per share in cash, or approximately $11.1 billion. In December, Gilead commenced a tender offer to purchase all outstanding common stock of Pharmasset. The acquisition was completed on January 17, 2012 at which time Pharmasset became a wholly-owned subsidiary of Gilead. Other Corporate Highlights In October, Gilead announced that it had entered into a licensing agreement with Boehringer Ingelheim (BI), under which BI granted Gilead exclusive worldwide rights for the research, development and commercialization of its novel non-catalytic site integrase inhibitors for HIV. This included the lead compound BI 224436, which has been evaluated in a Phase 1a dose- escalation study to assess bioavailability and pharmacokinetics in healthy volunteers. Also in October, Gilead announced that it had entered into an exclusive worldwide licensing and collaboration agreement with GlobeImmune, Inc. for the development and commercialization of therapeutic vaccine products for use in conjunction with Viread and other oral therapies for the treatment of chronic hepatitis B. Lastly, in October, Gilead announced a licensing agreement with Bristol-Myers Squibb (BMS) for BMS to develop and commercialize a fixed-dose combination containing BMS’s protease inhibitor atazanavir and Gilead’s cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of certain HIV medicines to potentially allow for one-pill, once-daily dosing.
Load more

Recommended publications
  • The Design, Synthesis and Optimization of Allosteric Hiv-1
    THE DESIGN, SYNTHESIS AND OPTIMIZATION OF ALLOSTERIC HIV-1 INTEGRASE INHIBITORS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Janet Antwi Graduate Program in Pharmaceutical Sciences The Ohio State University 2017 Dissertation Committee: Professor James R. Fuchs, Advisor Professor Werner Tjarks Professor Karl A. Werbovetz Copyright by Janet Antwi 2017 Abstract In the past quarter century, there has been tremendous progress in the discovery of antiretroviral therapy, making HIV/AIDS a manageable chronic disease. However, the HIV virus is relentless and continues to evolve under drug pressure to escape control and continue infection. The enzyme HIV integrase is responsible for the incorporation of viral double stranded DNA into a host chromosomal DNA and has recently become an attractive target in combating HIV resistance. Raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG) are three clinically approved active-site integrase inhibitors. Unfortunately, mutations of the enzyme observed in patients have resulted in resistance to thedrug in the clinic. A new approach to targeting integrase (IN) is the development of allosteric inhibitors that specifically target the protein-protein interaction between IN and its cellular cofactor LEDGF/p75. Recently discovered quinoline-based allosteric integrase inhibitor (ALLINI) B1224436 was the first compound to advance into clinical trials but was discontinued due to poor pharmacokinetic properties including low in vivo clearance. In addition, several reports have revealed the emergence of resistance due to mutation to quinoline based ALLINIs. Applying scaffold hopping approach, several pyridine-based, thiophenes, ii pyrazoles, isoquinolines and other heteroaromatic cores have been studied as ALLINIs.
    [Show full text]
  • Mutational Studies of Novel Screened Molecules Against Wild and Mutated HIV-1 Integrase Using Molecular Docking Studies Pawan Gupta1,2*, Prabha Garg2
    Research Article Mutational studies of novel screened molecules against wild and mutated HIV-1 integrase using molecular docking studies Pawan Gupta1,2*, Prabha Garg2 ABSTRACT Background and Aim: The screened molecules which proposed novel HIV-1 integrase inhibitors were collected from the literature. Mutational studies were performed to check whether these molecules are having good binding affinity against mutated HIV-1 IN or not using molecular docking technique. Materials and Methods: First, homology models of the mutated HIV-1 IN were prepared and subsequently all the models were refined and optimized in MODELLER program. Next, molecular docking studies were performed into the active site of mutated HIV-1 IN models using the proposed inhibitors in AutoDock 4.1 program. The results of these studies were compared with the wild type docking studies. Results: The docking studies were found that some of the screened molecules (ZINC1245110, 131614, 92749, ZINC05181828, and ZINC13147504) followed the same binding patterns (in term of locations, interactions, and binding score) as found with wild type HIV-1 IN. Conclusions: Computationally, the same binding patterns were exhibited by these molecules (ZINC1245110, 131614, 92749, ZINC05181828, and ZINC13147504) against mutated models as wild type. This elucidated that these molecules having susceptibility against the drug-resistant HIV-1 IN. Hence, these molecules may be used as a starting point to design novel inhibitors against mutated HIV-1 IN, which need to be confirmed experimentally. KEY WORDS: Docking, Drug resistance, Homology modeling, HIV-1 integrase, Mutation INTRODUCTION Drug resistance is the inevitable consequence of incomplete suppression of HIV-1 replication. The Human immuno-virus (HIV) causes AIDS.
    [Show full text]
  • This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By
    This project has been supported with unrestriced grants from AbbVie Gilead Sciences HEXAL Janssen-Cilag MSD ViiV Healthcare By Marcus Altfeld, Hamburg/Boston (USA) Achim Barmeyer, Dortmund Georg Behrens, Hannover Dirk Berzow, Hamburg Christoph Boesecke, Bonn Patrick Braun, Aachen Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Rika Draenert, Munich Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Gunar Günther, Windhoek (Namibia) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Christoph Lange, Borstel Thore Lorenzen, Hamburg Tim Niehues, Krefeld Christian Noah, Hamburg Ramona Pauli, Munich Ansgar Rieke, Koblenz Jürgen Kurt Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Bernhard Schaaf, Dortmund Ulrike Sonnenberg-Schwan, Munich Christoph D. Spinner, Munich Thomas Splettstoesser (Figures), Berlin Matthias Stoll, Hannover Hendrik Streeck, Essen/Boston (USA) Jan Thoden, Freiburg Markus Unnewehr, Dortmund Mechthild Vocks-Hauck, Berlin Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2015/16 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Christian Hoffmann, M.D., Ph.D. ICH Stadtmitte (Infektionsmedizinisches Centrum Hamburg) Glockengiesserwall 1 20095 Hamburg, Germany Phone: + 49 40 2800 4200 Fax: + 49 40 2800 42020 [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2015/16 have made every effort to provide information that is accurate and complete as of the date of publication.
    [Show full text]
  • Interbiotech Ritonavir
    InterBioTech FT-LSI940 Ritonavir Products Description Product Name: Ritonavir Syn: A 84538; ABT 538; Abbott 84538; NSC 693184; RTV; C₃₇H₄₈N₆O₅S₂ Cat N° : LSI940, 10mg LSI941, 50mg LSI942, 100mg LSI943, 500 mg Inquire >=1 g also available as 10 mM solution (1 mL in DMSO) CAS No.: 155213-67-5 MWt: 720.94 Purity: 99.55% (white solid) Melting Point: 175-178°C Solubility: 10 mM in DMSO; < 0.1 mg/mL in H2O Target: CYP3A4 Pathway: Proteaseome Storage:(L) store the product at -20°C (stable for 3 years) or +4°C (stable for 2 years) (M) Product Name: Ritonavir metabolite ( Desthiazolylmethyloxycarbonyl Ritonavir ) Cat N° : XMH680, 5mg XMH681, 10 mg XMH682, 50 mg CAS No.: 176655-55-3 MWt: 579.8 C₃₇H₄₈N₆O₅S₂ Technical and Scientific Information Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS. Biological activity: Ritonavir is an inhibitor of CYP3A4 mediated testosterone 6β-hydroxylation with mean Ki of 19 nM and also inhibits [1] tolbutamide hydroxylation with IC50 of 4.2 μM . Ritonavir is found to be a potent inhibitor of CYP3A-mediated biotransformations (nifedipine oxidation with IC50 of 0.07 mM, 17alpha-ethynylestradiol 2-hydroxylation with IC50 of 2 mM; terfenadine hydroxylation with IC50 of 0.14 mM). Ritonavir is also an inhibitor of the reactions mediated by [2] CYP2D6 (IC50=2.5 mM) and CYP2C9/10 (IC50=8.0 mM) . Ritonavir results in an increase in cell viability in uninfected human PBMC cultures. Ritonavir markedly decreases the susceptibility of PBMCs to apoptosis correlated with lower levels of caspase-1 expression, decreases in annexin V staining, and reduces caspase-3 activity in uninfected human PBMC cultures.
    [Show full text]
  • The Impact of Modern Antiretroviral Therapy on Lipid Metabolism of HIV-1 Infected Patients
    Chapter 6 The Impact of Modern Antiretroviral Therapy on Lipid Metabolism of HIV-1 Infected Patients Joel da Cunha, Luciana Morganti Ferreira Maselli, Sérgio Paulo Bydlowski and Celso Spada Additional information is available at the end of the chapter http://dx.doi.org/10.5772/61061 1. Introduction The highly active antiretroviral therapy (HAART) is the most efficient and safe alternative against HIV-1 infection, to allow the restoration of the immune system, with consequent reduction in mortality rate, increased survival and quality of life of infected patients. Apart from the great benefits of the use of different HAART regimens, laboratory and clinical experience has shown that HAART can induce severe and considerable adverse effects on metabolic complications of lipid metabolism, characterized by signs of dyslipidemia, increased risk of cardiovascular disease and even an increased risk of atherosclerosis. In this context, the class of protease inhibitors has been associated with a higher level of changes of lipid metab‐ olism and an increased risk for cardiovascular disease. In turn, the search for different therapeutic strategies to reverse HAART-associated lipid disorders has led to the use of less metabolically active antiretroviral drugs without compromising antiretroviral efficacy. Thus, the different interactions of antiretroviral drugs are recommended based on their degree of impact on lipid metabolism. Recently, fusion inhibitors, integrase strand transfer inhibitors, entry inhibitors, have been included in the therapeutic arsenal against HIV-1 infection, and are not associated with metabolic disorders, since their mechanisms of action are different from other classes of antiretrovirals. Instead, the use of hypolipidemic drug therapy (statins, fibrates, inhibitors of intestinal cholesterol) becomes necessary when HAART-associated dyslipidemia occurs or persists for a long period and when alterations in diet, exercise and other HAART strategies are ineffective.
    [Show full text]
  • Discovery of Novel Integrase Inhibitors Acting Outside the Active Site Through High-Throughput Screening
    molecules Article Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening 1 2, 2, 1 Cindy Aknin , Elena A. Smith y, Christophe Marchand z, Marie-Line Andreola , Yves Pommier 2 and Mathieu Metifiot 1,* 1 Laboratoire MFP, CNRS UMR5234, Université de Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux CEDEX, France; [email protected] (C.A.); [email protected] (M.-L.A.) 2 Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, CCR, NCI, NIH, 37 Convent Drive, Bethesda, MD 20892, USA; [email protected] (E.A.S.); [email protected] (C.M.); [email protected] (Y.P.) * Correspondence: mathieu.metifi[email protected]; Tel.: +33-557571739 Present addresses: Quality Control, Protein Sciences, A Sanofi Company, 1000 Research Parkway, y Meriden, CT 06450, USA. Present addresses: Center for Research Strategy, NCI, NIH, 31 Center Drive, Bethesda, MD 20892, USA. z Received: 20 September 2019; Accepted: 9 October 2019; Published: 12 October 2019 Abstract: Currently, an increasing number of drugs are becoming available to clinics for the treatment of HIV infection. Even if this targeted therapy is highly effective at suppressing viral replication, caregivers are facing growing therapeutic failures in patients, due to resistance with or without treatment adherence concerns. Accordingly, it is important to continue to discover small molecules that have a novel mechanism of inhibition. In this work, HIV integrase inhibitors were selected by high-throughput screening. Chemical structure comparisons enabled the identification of stilbene disulfonic acids as a potential new chemotype. Biochemical characterization of the lead compound stilbenavir (NSC34931) and a few derivatives was performed.
    [Show full text]
  • Hiv Integrase Mechanisms of Resistance to Raltegravir, Elvitegravir, and Dolutegravir Kyla Nicole Ross Wayne State University
    Wayne State University Wayne State University Theses 1-1-2015 Hiv Integrase Mechanisms Of Resistance To Raltegravir, Elvitegravir, And Dolutegravir Kyla Nicole Ross Wayne State University, Follow this and additional works at: https://digitalcommons.wayne.edu/oa_theses Part of the Biochemistry Commons, Bioinformatics Commons, and the Virology Commons Recommended Citation Ross, Kyla Nicole, "Hiv Integrase Mechanisms Of Resistance To Raltegravir, Elvitegravir, And Dolutegravir" (2015). Wayne State University Theses. 458. https://digitalcommons.wayne.edu/oa_theses/458 This Open Access Thesis is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Theses by an authorized administrator of DigitalCommons@WayneState. HIV INTEGRASE MECHANISMS OF RESISTANCE TO RALTEGRAVIR, ELVITEGRAVIR, AND DOLUTEGRAVIR by KYLA ROSS THESIS Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE 2015 MAJOR: BIOCHEMISTRY AND MOLECULAR BIOLOGY Approved By: Advisor Date © COPYRIGHT BY KYLA ROSS 2015 All Rights Reserved DEDICATION I dedicate this thesis to my late step brother Carlton Lowry. ii ACKNOWLEDGEMENTS I would like to thank everyone in the Kovari lab for their generous help with this thesis. I thank Ben for helping me with the manuscripts, the research, and the experiments and for being a great colleague and an awesome friend. I thank Brad for answering the most complicated questions, for suggesting alternative approaches, and for being a great friend. I thank Cathy for being there to listen, the awesome conversations and for being a great colleague. I would like to thank Tamaria for giving me this project and offering her professional input.
    [Show full text]
  • The Emerging Role of HIV-1 Integrase in Virion Morphogenesis
    viruses Review Going beyond Integration: The Emerging Role of HIV-1 Integrase in Virion Morphogenesis Jennifer L. Elliott and Sebla B. Kutluay * Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, MO 63110, USA; [email protected] * Correspondence: [email protected] Received: 26 August 2020; Accepted: 7 September 2020; Published: 9 September 2020 Abstract: The HIV-1 integrase enzyme (IN) plays a critical role in the viral life cycle by integrating the reverse-transcribed viral DNA into the host chromosome. This function of IN has been well studied, and the knowledge gained has informed the design of small molecule inhibitors that now form key components of antiretroviral therapy regimens. Recent discoveries unveiled that IN has an under-studied yet equally vital second function in human immunodeficiency virus type 1 (HIV-1) replication. This involves IN binding to the viral RNA genome in virions, which is necessary for proper virion maturation and morphogenesis. Inhibition of IN binding to the viral RNA genome results in mislocalization of the viral genome inside the virus particle, and its premature exposure and degradation in target cells. The roles of IN in integration and virion morphogenesis share a number of common elements, including interaction with viral nucleic acids and assembly of higher-order IN multimers. Herein we describe these two functions of IN within the context of the HIV-1 life cycle, how IN binding to the viral genome is coordinated by the major structural protein, Gag, and discuss the value of targeting the second role of IN in virion morphogenesis. Keywords: HIV-1; integrase; maturation; integrase–RNA interactions; protein–RNA interactions 1.
    [Show full text]
  • Hoffmann Rockstroh |
    Hoffmann| Rockstroh HIV 2015/2016 www.hivbook.com Medizin Fokus Verlag This project has been supported with unrestriced grants from AbbVie Gilead Sciences HEXAL Janssen-Cilag MSD ViiV Healthcare By Marcus Altfeld, Hamburg/Boston (USA) Achim Barmeyer, Dortmund Georg Behrens, Hannover Dirk Berzow, Hamburg Christoph Boesecke, Bonn Patrick Braun, Aachen Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Rika Draenert, Munich Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Gunar Günther, Windhoek (Namibia) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Christoph Lange, Borstel Thore Lorenzen, Hamburg Tim Niehues, Krefeld Christian Noah, Hamburg Ramona Pauli, Munich Ansgar Rieke, Koblenz Jürgen Kurt Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Bernhard Schaaf, Dortmund Ulrike Sonnenberg-Schwan, Munich Christoph D. Spinner, Munich Thomas Splettstoesser (Figures), Berlin Matthias Stoll, Hannover Hendrik Streeck, Essen/Boston (USA) Jan Thoden, Freiburg Markus Unnewehr, Dortmund Mechthild Vocks-Hauck, Berlin Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2015/16 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Christian Hoffmann, M.D., Ph.D. ICH Stadtmitte (Infektionsmedizinisches Centrum Hamburg) Glockengiesserwall 1 20095 Hamburg, Germany Phone: + 49 40 2800 4200 Fax: + 49 40 2800 42020 [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2015/16 have made every effort to provide information that is accurate and complete as of the date of publication.
    [Show full text]
  • BI 224436 | Medchemexpress
    Inhibitors Product Data Sheet BI 224436 • Agonists Cat. No.: HY-18595 CAS No.: 1155419-89-8 Molecular Formula: C₂₇H₂₆N₂O₄ • Molecular Weight: 442.51 Screening Libraries Target: HIV; HIV Integrase Pathway: Anti-infection; Metabolic Enzyme/Protease Storage: Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended. SOLVENT & SOLUBILITY In Vitro DMSO : ≥ 50 mg/mL (112.99 mM) * "≥" means soluble, but saturation unknown. Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 2.2598 mL 11.2992 mL 22.5984 mL Stock Solutions 5 mM 0.4520 mL 2.2598 mL 4.5197 mL 10 mM 0.2260 mL 1.1299 mL 2.2598 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.65 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.65 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.65 mM); Clear solution BIOLOGICAL ACTIVITY Description BI 224436 is a novel HIV-1 noncatalytic site integrase inhibitor with EC50 values of less than 15 nM against different HIV-1 laboratory strains. IC₅₀ & Target EC50: 15 nM (HIV-1)[1] In Vitro BI 224436 has cellular cytotoxicity of more than 90 μM. BI 224436 has a low, 2.1-fold decrease in antiviral potency in the presence of 50% human serum.
    [Show full text]
  • HIV Pipeline 2017: Targets in the HIV Lifecycle Targets in the HIV Lifecycle 1 HIV Attaches to a CD4 Cell
    ISSN 1472-4863 HIV pipeline2017 New drugs in development htb supplement: 2017 Vol 18:(1) HIV pipeline 2017: targets in the HIV lifecycle Targets in the HIV lifecycle 1 HIV attaches to a CD4 cell. 1 HIV Monoclonal Entry inhibitors 2 HIV enters a CD4 cell and gp120 antibodies (mAb) fostemsavir capsid HIV proteins and enzymes combinectin gp41 UB-421 (CD4 receptor) are released into the cell. ibalizumab (CD4 receptor) 3 Reverse transcriptase (RT) CD4 receptor (CCR5 recept.) makes double strand HIV. CCR5 coreceptor PRO-140 4 Integrase enables HIV to join the cell DNA. NRTIs/NtRTIs 2 5 Protease cuts and (nukes) reassembles new HIV. EFdA (MK-8591) 6 Each cell produces GS-9131 CD4 hundreds of new virions. HIV RNA cell NNRTIs (non-nukes) 3 Cell doravirine nucleus Protease inhibitor elsufavirine HIV DNA New viral GS-PS1 rilpivirine LA material 4 5 Capsid inhibitor Integration GS-CA1 INIs (or INSTIs) Maturation Maturation bictegravir and budding inhibitor cabotegravir 6 cabotegravir LA GSK3640254 C O N T E N T S HIVi-base.info i-Base (2017)(www.i-Base.info) New HIV HIV pipeline 2017 2 Introduction to HIV pipeline in 2017 2 Figure 1: HIV pipeline 2017: targets in the HIV lifecycle 3 Recently approved new HIV drugs 3 • Raltegravir HD • Generic dolutegravir • Generic TDF/FTC Submitted applications: completed phase 3 results 4 • Darunavir/cobicistat/FTC/TAF - FDC • Bictegravir/FTC/TAF - FDC • Dolutegravir/rilpivirine - two-drug FDC Table 1: HIV pipeline compounds by development phase 5 Compounds in phase 3 development 6 • Doravirine - NNRTI • Cabotegravir
    [Show full text]
  • Clinical Pharmacology Related Considerations
    Clinical Pharmacology Related Considerations. David Back University of Liverpool David Back UK University of Liverpool Disclosures • Honoraria received for advisory boards and lectures from AbbVie, BMS, Gilead, Merck, ViiV, Janssen, Teva • Educational grants for www.hep-druginteractions.org and www.hiv-druginteractions.org from AbbVie, BMS, Gilead, Janssen, Merck, ViiV Overview 1 The changing face of treatment. 2 3 Antiretroviral Therapy: Past, Present & Future 1. New Drugs The Integrase 2. 2 Drug Regimens era (2DR) Single 3. Long acting Triple drug tablet agents? therapy regimens ZDV monotherapy HIV-1 discovered 1983 1987 1996 2006 2012/13 2018ff Overview of Clinical Guidelines and First-Line Antiretroviral Treatment Options DRV/r RAL RPV TDF/FTC DRV/c DTG EFV TAF/FTC EVG/c ABC/3TC Overview of Clinical Guidelines and First-Line Antiretroviral Treatment Options DRV/r RAL RPV TDF/FTC DRV/c DTG EFV TAF/FTC EVG/c ABC/3TC Raltegravir (RAL) 1200 mg once daily (QD) versus RAL 400 mg twice daily (BID), in combination with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in previously untreated HIV-1 infection through week 96 P. Cahn for the ONCEMRK Study Group IAS 2017: TULBPEB20 First-Line ART Regimens for Adults WHO Guidelines June 2016 C EFV at lower dose of 400 mg e Safety and efficacy data on the use of EFV400 in pregnant women, people with HIV/TB coinfection and adolescents younger than 12 years of age are not yet available. Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum Marta Boffito, Chelsea and Westminster Hospital, Curr Opin HIV AIDS 2017; 12: 339-342 United Kingdom.
    [Show full text]